Q&A: GSK vac­cine leader Judy Stew­art nav­i­gates vac­ci­na­tion slumps, al­ways-on mar­ket­ing and in­no­vat­ing da­ta tools

It’s been a tough cou­ple of years for tra­di­tion­al vac­cine mak­ers. While the Covid-19 pan­dem­ic spurred a flur­ry of in­no­va­tion and turned a white-hot spot­light on the footrace for Covid vac­cine ap­provals, rou­tine vac­ci­na­tion rates plum­met­ed.

Ear­ly re­stric­tions, on­go­ing health pre­cau­tions and sup­ply chain is­sues caused mil­lions of peo­ple to skip rec­om­mend­ed vac­cines by the end of 2021. The World Health Or­ga­ni­za­tion re­cent­ly re­port­ed that 2021 suf­fered “the largest sus­tained de­cline in child­hood vac­ci­na­tions” in 30 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER